In other trials of GLP-1 RA in patients with T2D and high CV risk, including 8.6% to 24% having HF at baseline, treatment with exenatide [42], semaglutide [43,44], lixisenatide [45], and dulaglutide [46] did not significantly reduce the risk of HHF. This evidence concerns the gene GLP1R and hydrops fetalis.